-+ 0.00%
-+ 0.00%
-+ 0.00%

INSMED ANNOUNCES POSITIVE 12-MONTH DATA FROM THE ONGOING OPEN-LABEL EXTENSION STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Reuters·07/16/2026 11:00:04

Please log in to view news